Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis.
We report a patient with agnogenic myeloid metaplasia associated with debilitating bone pain due to increased bone turnover and osteosclerosis. Treatment with etidronate at a dose of 6 mg/kg per day on alternate months resulted in a complete recovery of bone symptoms and normalization of metabolic parameters of bone turnover; unexpectedly, a sustained haematological improvement was also observed after several months of therapy, suggesting that bone marrow microenvironment improvement was able to restore a nearly normal haemopoiesis. We suggest that diphosphonate therapy may be of value in patients with AMM and increased bone turnover.
Sivera
P
P
Dipartimento di Scienze Cliniche, Università di Torino, Italy.
Cesano
L
L
Guerrasio
A
A
Camaschella
C
C
Mazza
U
U
D000368:Aged; D012968:Etidronic Acid / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010026:Osteosclerosis / Q000188:drug therapy*; D055728:Primary Myelofibrosis / Q000097:blood / Q000188:drug therapy*
D012968:Etidronic Acid